R Scott McIvor Selected Research

Iduronidase (alpha-L-Iduronidase)

1/2021	Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I.
1/2021	Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
9/2020	Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10.
8/2020	Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease.
1/2020	Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.
1/2019	ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome.
1/2017	Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease.
1/2017	Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
1/2014	Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease.
1/2013	Quantitative analysis of α-L-iduronidase expression in immunocompetent mice treated with the Sleeping Beauty transposon system.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R Scott McIvor Research Topics

Disease

11	Mucopolysaccharidosis I (Hurler Syndrome) 01/2021 - 06/2004
7	Neoplasms (Cancer) 04/2013 - 03/2002
5	Mucopolysaccharidoses 07/2021 - 05/2007
3	Inflammation (Inflammations) 01/2022 - 01/2020
3	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2017 - 07/2009
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 05/2006
2	Metabolic Diseases (Metabolic Disease) 01/2019 - 01/2017
2	Mucopolysaccharidosis II (Hunter Syndrome) 01/2018 - 01/2017
2	Hemophilia A (Haemophilia) 01/2017 - 04/2005
2	Thymoma (Thymic Carcinoma) 07/2007 - 02/2006
2	Tyrosinemias (Tyrosinemia) 07/2007 - 11/2006
2	Carcinoma (Carcinomatosis) 11/2005 - 12/2004
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/2003 - 03/2002
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 07/2021
1	Infections 01/2021
1	Fever (Fevers) 01/2021
1	Congenital Abnormalities (Deformity) 01/2020
1	Mucopolysaccharidosis VII (Sly Syndrome) 01/2017
1	Central Nervous System Diseases (CNS Diseases) 01/2017
1	Colonic Neoplasms (Colon Cancer) 04/2013
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2013
1	Neuromuscular Diseases (Neuromuscular Disease) 01/2013
1	Chronic Pain 05/2010
1	Pain (Aches) 05/2010
1	Virus Diseases (Viral Diseases) 01/2009
1	Cerebellar Diseases (Cerebellar Syndrome) 01/2008
1	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2008
1	Nervous System Diseases (Neurological Disorders) 01/2008
1	Hypersensitivity (Allergy) 07/2007
1	Sarcoma (Soft Tissue Sarcoma) 02/2007
1	Inborn Genetic Diseases (Disease, Hereditary) 02/2006
1	Hematologic Neoplasms (Hematological Malignancy) 08/2005
1	Hemorrhage 04/2005
1	Hepatocellular Carcinoma (Hepatoma) 12/2004

Drug/Important Bio-Agent (IBA)

11	Iduronidase (alpha-L-Iduronidase)IBA 01/2021 - 06/2004
8	GlycosaminoglycansIBA 01/2022 - 07/2011
8	EnzymesIBA 01/2021 - 05/2007
5	DNA (Deoxyribonucleic Acid)IBA 04/2013 - 04/2005
4	TransposasesIBA 02/2011 - 12/2004
3	Pharmaceutical PreparationsIBA 12/2004 - 03/2002
2	Dermatan SulfateIBA 09/2020 - 01/2017
2	Heparitin Sulfate (Heparan Sulfate)IBA 01/2020 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 07/2007 - 04/2005
2	Messenger RNA (mRNA)IBA 07/2007 - 07/2007
2	lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA 07/2007 - 02/2006
2	Methotrexate (Mexate)FDA LinkGeneric 08/2005 - 03/2002
1	ElastinIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2021
1	Sulfates (Sulfates, Inorganic)IBA 08/2020
1	CollagenIBA 01/2020
1	HydrolasesIBA 01/2019
1	AlbuminsIBA 01/2019
1	Iduronic Acid (Iduronate)IBA 01/2018
1	Iduronate SulfataseIBA 01/2017
1	GlucuronidaseIBA 01/2017
1	EndonucleasesIBA 04/2015
1	IntegrinsIBA 04/2013
1	Liposomes (Liposome)IBA 04/2013
1	Peptides (Polypeptides)IBA 04/2013
1	LigandsIBA 04/2013
1	DystrophinIBA 01/2013
1	Glycoproteins (Glycoprotein)IBA 01/2013
1	AngiostatinsIBA 02/2011
1	EndostatinsIBA 02/2011
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2011
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2009
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2008
1	polyglutamineIBA 01/2008
1	Antisense RNA (Anti-Sense RNA)IBA 01/2008
1	Ataxin-1IBA 01/2008
1	Protein Kinases (Protein Kinase)IBA 07/2007
1	LuciferasesIBA 02/2007
1	fumarylacetoacetase (fumarylacetoacetate hydrolase)IBA 11/2006
1	DNA-Activated Protein KinaseIBA 02/2006
1	Biological ProductsIBA 02/2006
1	Mitogen-Activated Protein KinasesIBA 11/2005
1	Antineoplastic Agents (Antineoplastics)IBA 08/2005
1	Factor VIII (Coagulation Factor VIII)IBA 04/2005
1	Complementary DNA (cDNA)IBA 04/2005
1	Kanamycin KinaseIBA 12/2004
1	nitrobenzylthioinosine 5'-monophosphateIBA 03/2003
1	Trimetrexate (JB11)FDA Link 03/2003
1	Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)IBA 03/2003
1	ProdrugsIBA 03/2003
1	NucleosidesIBA 03/2003

Therapy/Procedure

9	Therapeutics 01/2021 - 03/2002
2	Drug Therapy (Chemotherapy) 01/2017 - 03/2003
1	Tissue Expansion 01/2020
1	Intranasal Administration 01/2017
1	Transplantation 04/2015
1	Cell Transplantation 05/2006